• / Free eNewsletters & Magazine
  • / My Account
Home>TherapeuticsMD Announces Closing of Common Stock Offering

TherapeuticsMD Announces Closing of Common Stock Offering

TherapeuticsMD Announces Closing of Common Stock Offering

09/29/2017

TherapeuticsMD Announces Closing of Common Stock Offering

TherapeuticsMD, Inc. (NYSE American: TXMD) today announced the closing of its previously announced underwritten public offering of 12.4 million shares of its common stock. At closing, TherapeuticsMD received net proceeds from the offering of approximately $68.5 million, after deducting offering expenses. All of the shares in the offering were sold by TherapeuticsMD.

TherapeuticsMD intends to use a majority of the net proceeds from the offering to fund pre-commercialization and commercialization activities for TX-004HR, the Company’s applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause, and TX-001HR, the Company’s bio-identical hormone therapy combination of 17ß- estradiol and progesterone in a single, oral softgel drug candidate for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause in post-menopausal women with an intact uterus, for other research, clinical trials, clinical formulation and development and for working capital and general corporate purposes.

J.P. Morgan is acting as sole book-running manager for the offering.

TherapeuticsMD has filed a shelf registration statement on Form S-3, including a prospectus supplement and accompanying prospectus, with the Securities and Exchange Commission (the “SEC”), relating to the public offering of the shares of common stock described above. These documents contain important information that you should consider when making your investment decision. TherapeuticsMD’s SEC filings are available to the public from the SEC’s website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to these securities may also be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewater, NY 11717, or telephone: 866-803-9204.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA™ technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company’s late stage clinical pipeline includes two phase 3 product candidates: TX-001HR for treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause and TX-004HR for treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD® and BocaGreenMD® brands.

©2017 Morningstar Advisor. All right reserved.